Company

Khondrion logo

Khondrion is a clinical-stage biopharmaceutical company discovering and developing therapies targeting primary mitochondrial disease. The company is advancing its proprietary science through a wholly-owned clinical and preclinical small molecule pipeline of potential medicines. 

The company’s in-house discovery engine is using unique live-cell imaging technologies and predictive disease models to build a portfolio of promising compounds. Active discovery programmes are underway developing new therapies, biomarkers and new read-out technologies in the field of primary mitochondrial diseases.

To accelerate the discovery and development of its potential medicines for mitochondrial diseases, Khondrion collaborates with a global clinical and academic network and patient organisations internationally.

Sonlicromanol, Khondrion’s most advanced product is currently being evaluated in an international multi-center phase 2b clinical trial and an open label extension study in adult patients.  A phase 2 study in children is recruiting. 

Khondrion BV

Transistorweg 5C

6534 AT Nijmegen

The Netherlands

+31 (0)24 7635000

https://www.khondrion.com

More companies in this area

Gatt Technologies

GATT Technologies is a privately owned, clinical-stage, medical device company.

Staten Biotechnology

Staten Biotechnology aims to develop novel and innovative strategies for the prevention of cardiovascular events, the largest unmet medical need in dyslipidemia.

SPL Medical

SPL Medical is strongly committed to improve MRI imaging to enable a much more precise, effective and patient friendly diagnosis of cancer metastasis.

QM Diagnostics

QM Diagnostics is an internationally operating, independent and innovative diagnostic microbiological laboratory.

We are specialized in health monitoring of small laboratory animals used for biomedical research.

Cardiacbooster

Developing the next generation of percutaneous left ventricular assist devices.

ATRO Medical

ATRO Medical is working hard on the transition to the clinic and the first implantation of a Trammpolin™ meniscus prosthesis in the patient is expected in 2020.

Settle at Novio Tech Campus!

Connect with Novio Tech Campus!